Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography

Artificial Intelligence Clinical Trial

— PEAICTPA  

Official title:

Prediction of Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05482269
• Other study ID #: PEAICTPA
• Status: Recruiting
• Start date: January 1, 2011
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: Shengjing Hospital
• Contact: DONG JIA
• Phone: +86-18940252800
• Email: jiadong0101[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators aim to build a predictive tool for Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography.

Description:

This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital. The investigators aim to build a predictive tool for Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography.

Eligible patients were randomized in some ratio into derivation and validation cohorts. The derivation cohort was used to develop and evaluate a multivariable logistic regression model for predicting the outcomes of interest. The discriminatory power was evaluated by comparing the nomogram to the established risk stratification systems. The consistency of the nomogram was evaluated using the validation cohort.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: December 31, 2025
• Est. primary completion date: July 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age of = 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography

Exclusion Criteria:

• pregnancy

• reception of reperfusion treatment before admission

• missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.

Related Conditions & MeSH terms

• Artificial Intelligence
• Clinical Deterioration
• Deterioration, Clinical
• Embolism
• Embolism and Thrombosis
• Pulmonary Embolism
• Pulmonary Embolism and Thrombosis
• Thrombosis

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
China	Shengjing Hospital	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
Shengjing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events	The outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission. Adverse outcomes were defined as deaths, the need for mechanical ventilation, the need for cardiopulmonary resuscitation, and the need for life-saving vasopressor and reperfusion treatment.	30 days
Secondary	Incidence of Treatment-Emergent Adverse Events	The outcomes of interest were defined as the occurrence of adverse outcomes within 2 years after admission. Adverse outcomes were defined as deaths, the need for mechanical ventilation, the need for cardiopulmonary resuscitation, and the need for life-saving vasopressor and reperfusion treatment.	2 years